Autologous Stem Cell Therapy and its Effects on COPD:
A Pilot Study

Author: Jack Coleman Jr., M.D.

Today more than 600 million people suffer from chronic obstructive pulmonary disease (COPD) worldwide. Although there is no cure for COPD, recent advancements in stem cell therapy have made it possible not only to relieve symptoms, but to promote healing within the lungs themselves.

After testing approximately 100 patients, the Lung Institute has discovered that within three months of treatment, 84 percent of patients found their quality of life had improved. Among other promising statistics this discovery could change lives significantly. For millions of people suffering from COPD, a natural decline in pulmonary health is a harsh reality. Based on these results, stem cell therapy could be the answer they’ve been looking for.

For more details and statistics on the effects of stem cell therapy on pulmonary function improvement, continue reading below.

The Problem with Chronic Pulmonary Diseases

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disorder that often occurs as a result of prolonged cigarette smoking, second-hand smoke, and polluted air or working conditions. COPD is the most prevalent form of chronic lung disease. The physiological symptoms of COPD include shortness of breath (dyspnea), cough, and sputum production, exercise intolerance and reduced Quality of Life (QOL). These signs and symptoms are brought about by chronic inflammation of the airways, which restricts breathing. When fibrotic tissues contract, the lumen is narrowed, compromising lung function. As histological studies confirm, airway fibrosis and luminal narrowing are major features that lead to airflow limitation in COPD 1-3.

Today, COPD is a serious global health issue, with a prevalence of 9-10% of adults aged 40 and older4. And the prevalence of the disease is only expected to rise. Currently COPD accounts for 27% of tobacco related deaths and is anticipated to become the fourth leading cause of death worldwide by 2030 5. Today, COPD affects approximately 600 million individuals—roughly 5% of the world’s population 6. Despite modern medicine and technological advancements, there is no known cure for COPD.

The difficulty in treating COPD and other lung diseases rests in the trouble of stimulating alveolar wall formation15. Until recently, treatment has been limited by two things: a lack of understanding of the pathophysiology of these disease processes on a molecular level and a lack of pharmaceutical development that would affect these molecular mechanisms. This results in treatment focused primarily in addressing the symptoms of the disease rather than healing or slowing the progression of the disease itself.

The result is that there are few options available outside of bronchodilators and corticosteroids7. Although lung transplants are performed as an alternative option, there is currently a severe shortage of donor lungs, leaving many patients to die on waiting lists prior to transplantation. Lung transplantation is also a very invasive form of treatment, commonly offering poor results, a poor quality of life with a 5-year mortality rate of approximately 50%, and a litany of health problems associated with lifelong immunosuppression13.

However, it has been shown that undifferentiated multipotent endogenous tissue stem cells (cells that have been identified in nearly all tissues) may contribute to tissue maintenance and repair due to their inherent anti-inflammatory properties. Human mesenchymal stromal cells have been shown to produce large quantities of bioactive factors including cytokines and various growth factors which provide molecular cueing for regenerative pathways. This affects the status of responding cells intrinsic in the tissue 18. These bioactive factors have the ability to influence multiple immune effector functions including cell development, maturation, and allo-reactive T-cell responses 19. Although research on the use of autologous stem cells (both hematopoietic and mesenchymal) in regenerative stem cell therapy is still in the early stages of implementation, it has shown substantive progress in treating patients with few if any adverse effects.

Summary of Process

The Lung Institute (LI) provided treatment by harvesting autologous stem cells (hematopoietic stem cells and mesenchymal stromal cells) by withdrawing adipose tissue (fat), bone marrow or peripheral blood. These harvested cells are isolated and concentrated, and along with platelet-rich plasma, are then reintroduced into the body and enter the pulmonary vasculature (vessels of the lungs) where cells are trapped in the microcirculation (the “pulmonary trap”). Alternatively, nebulized stem cells are reintroduced through the airways in patients who have undergone an adipose (fat tissue) treatment.


Individuals diagnosed with COPD were tracked by the Lung Institute to measure the effects of treatment via either the venous protocol or adipose protocol on both their pulmonary function as well as their Quality of Life.

Pulmonary Function Test (PFT)

All PFTs were performed according to national practice guideline standards for repeatability and acceptability8-10. On PFTs, pre-treatment data was collected through on-site testing or through previous medical examinations by the patient’s primary physician (if done within two weeks). The test was then repeated by their primary physician 6 months after treatment.*

* Due to the examination information required from primary physicians, only 25 out of 100 patients are reflected in the PFT data.

Quality of Life Survey (QLS) and Quality Improvement Score (QIS)

Patients with progressive COPD will typically experience a steady decrease in their Quality of Life. Given this development, a patient’s Quality of Life score is frequently used to define additional therapeutic effects, with regulatory authorities frequently encouraging their use as primary or secondary outcomes17.

On quality of life testing, data was collected through the implementation of the Clinical COPD Questionnaire (CCQ) based survey17. The survey measured the patient’s self-assessed quality of life on a 0-6 scale, with adverse Quality of Life correlated in ascending numerical order. It was implemented in three stages: pre-treatment, 3-months post-treatment, and 6-months post-treatment. The survey measured two distinct outcomes: the QLS score, which measured the patient’s self-assessed quality of life score, and the QIS, a percentage-based measurement determining the proportion of patients within the sample that experienced QLS score improvements.


Over the duration of six months, the results of 100 patients treated for COPD through venous and adipose based therapies were tracked by the Lung Institute in order to measure changes in pulmonary function and any improvement in Quality of Life.

Of the 100 patients treated by the Lung Institute, 64 were male (64%) and 36 were female (36%). Ages of those treated range from 55-88 years old with an average age of 71. Throughout the study, 82 (82%) were treated with venous derived stem cells, while 18 (18%) were treated from stem cells derived from adipose tissue.


* The survey measured the patient’s self-assessed quality of life on a 0-6 scale, with adverse Quality of Life correlated in ascending numerical order.

Over the course of the study, the patient group averaged an increase of 35.5% to their Quality of Life (QLS) score within three months of treatment. While in the QIS, 84% of all patients found that their Quality of Life score had improved within three months of treatment (figure 1.3).

quality-of-life-improvementWithin the PFT results, 48% of patients tested saw an increase of over 10% to their original pulmonary function with an average increase of 16%. During the three to six month period after treatment, patients saw a small decline in their progress, with QLS scores dropping from 35.5% to 32%, and the QIS from 84% to 77%.
Fletcher and Peto’s work shows that patient survival rate can be improved through appropriate or positive intervention14 (figure 1.4). It remains to be seen if better quality of life will translate to longevity, but if one examines what factors allow for improved quality of life such as improvement in oxygen use, exercise tolerance, medication use, visits to the hospital and reduction in disease flare ups then one can see that quality of life improves in association with clinical improvement.


Currently the most utilized options for treating COPD are bronchodilator inhalers with or without corticosteroids and lung transplant – each has downsides. Inhalers are often used incorrectly11, are expensive over time, and can only provide temporary relief of symptoms. Corticosteroids, though useful, have risk of serious adverse side effects such as infections, blood sugar imbalance, and weight gain to name a few 16. Lung transplants are expensive, have an adverse impact on quality of life and have a high probability of rejection by the body the treatment of which creates a new set of problems for patients. In contrast, initial studies of stem cells treatments show efficacy, lack of adverse side effects and may be used safely in conjunction with other treatments.


Through the data collected by the Lung Institute, developing methodologies for this form of treatment are quickly taking place as other entities of the medical community follow suit. In a recent study of regenerative stem cell therapy done by the University of Utah, patients exhibited improvement in PFTs and oxygen requirement compared to the control group with no acute adverse events12. Through the infusion of stem cells derived from the patient’s own body, stem cell therapy minimizes the chance of rejection to the highest degree, promotes healing and can improve the patient’s pulmonary function and quality of life with no adverse side effects.

Although more studies using a greater number of patients is needed to further examine objective parameters such as PFTs, exercise tests, oxygen, medication use and hospital visits, larger sample sizes will also help determine if one protocol is more beneficial than others. With deeper research, utilizing economic analysis along with longer-term follow up will answer questions on patient selection, the benefits of repeated treatments, and a possible reduction in healthcare costs for COPD treatment.

The field of Cellular Therapy and Regenerative Medicine is rapidly advancing and providing effective treatments for diseases in many areas of medicine.The Lung Institutes strives to provide the latest in safe, effective therapy for chronic lung disease and maintain a leadership role in the clinical application of these technologies.

In a landscape of scarce options and rising costs, the Lung Institute believes that stem cell therapy is the future of treatment for those suffering from COPD and other lung diseases. Although data is limited at this stage, we are proud to champion this form of treatment while sharing our findings.

  1. Kuwano K, Bosken C, Pare P, Bai T, Wiggs B, Hogg J. Small airways dimensions in asthma and chronic obstructive pulmonary disease. Am Rev Respir Dis 1993; 148: 1220-25
  2. Hogg J, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-53.
  3. Niewoehner D. Structure-function relationships: the pathophysiology of airflow obstruction. In: Stockley R, Rnnard S. Rabe K, Celli B, eds. Chronic Obstructive Pulmonary Disease. Hoboken, NJ: Blackwell, 2007: 3-19.
  4. Halbert R, Natoli J. Gano A, Badamgarav E, Buist A, Mannino D. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006; 28: 423-32.
  5. Fernando J Martinez, James F Donohue, Stephen I Rennard. The future of chronic obstructive pulmonary disease treatment-difficulties of and barriers to drug development. Lancet 2011; 378: 1027-37.
  6. Michelle J. Hansen, Rosa C. Gualano, Steve Bozinovski, Ross Vlahos, Gary P. Anderson. Therapeutic prospects to treat skeletal muscle wasting in COPD (chronic obstructive lung disease). Pharmacology & Therapy 2006; 109: 162-172.
  7. European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of Chronic Obstructive Pulmonary Disease (COPD). London: European Medicines Agency, 2010.
  8. Wanger J, Clausen JL, Coastes A, et al. Standardisation of the measurement of lung volumes. Eur Respir J 2005; 26(3): 511-22.
  9. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26(2):319-38. ATS/ERS statement on respiratory muscle testing. Am J Respir Crit Care Med 2002; 166(4):518-624.
  10. Macintyre N, Crapo RO, Viegi G, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005; 26 (4): 720-35.
  11. Int J Chron Obstruct Pulmon Dis. 2008 Sep; 3(3): 371–384.
  12. J. Tuma, F. Silva, A.A. Winters, C. Bartlett, A.N. Patel. Maison de Sante. Lima, Peru; University of Utah, Salt Lake City, UT.
  13. Viranuj Sueblinvong, MD and Daniel J. Weiss, M.D., PHD. Stem Cells and Cell Therapy Approaches in Lung Biology and Diseases. 2010.
  14. Tantucci C, Modina D. Lung function decline in COPD. International Journal of Chronic Obstructive Pulmonary Disease. 2012; 7:95-99. doi:10.2147/COPD.S27480.
  15. Massaro G, Massaro D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nas Med 1997; 3: 675-77.
  16. Samy Suissa, Valerie Patenaude, Francesco Lapi, Pierre Ernst. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013; 68: 1029-1036.
  17. Clinical COPD Questionnaire. Accessed October 28, 2015.
  18. Tracey L. Bonfield, Arnold I. Caplan. Adult Mesenchymal Stem Cells: An Innovative Therapeutic for Lung Diseases. Discovery Medicine. April 2010; 9(47): 337-345.
  19. Giselle Chamberlain, James Fox, Brian Ashton, Jim Middleton. Mesenchymal Stem Cells: Their Phenotype, Differentiation Capacity, Immunological Features, and Potential for Homing. Stem Cells. 2007; 25:2739-2749.

If you would like to find out more about our available treatment options, please contact one of our patient care coordinators today at (800) 729-3065 to schedule a free consultation.
Download Printable Document


  1. Dr. Mark C

    2 months ago

    Some people ill, in closed room, can have exhaled CO2 from breath build up in room, giving added “Air hunger”, and making you think less clearly. LBL Published papers on this. Suggest monitoring CO2 in room and if >700ppm, need more fresh air. See I bought $90 meter & helpful to feel better without wasting heating or cooling more than needed

  2. sh

    3 months ago

    Dear Christine,

    Thanks for contacting us. Unfortunately, we are unable to find you or your husband in our records. Due to medical privacy regulations, we cannot discuss personal medical information in this forum. We take pride in our patient care and follow up, and if we are in error, please give us the chance to make it right by contacting us at (855) 313-1149.

    Best Regards, 
    The Lung Institute

  3. Christine

    3 months ago

    My husband has already had the treatment and it
    failed. No change whatsoever. The follow up at the lung
    institute is very, very poor. One would think that they would want to know WHY, that is the 12,000.00

  4. PB

    3 months ago

    Dear Charlotte,

    Thanks for your questions. Recently, we changed our questionnaire, so we’re currently analyzing patients that were treated January 2015 and after to be consistent in our data collection and reporting. In this case, we will have to wait until January 2016 to start recording one year follow-up data. At this point, since we’re a relatively new company (3 years old), we have not yet been able to collect enough one year follow-up data as of yet to have significant results. However, we are currently collecting data for one year follow-ups, and once we have adequate data, we will report it.

    Best Regards,

    The Lung Institute

  5. PB

    3 months ago

    Dear Alice,

    First and foremost, we’re sorry to hear about the difficulty you’ve been experiencing with COPD. Because of the personal nature of your question, it’s best to contact us to speak one-on-one with a patient coordinator. Our patient coordinators have a wealth of knowledge about stem cells, treatment options, cost and candidacy, and they can discuss more personal questions, like yours, in detail over the phone. So, feel free to contact us at (855) 313-1149, and we look forward to speaking with you soon.

    Kind Regards,

    The Lung Institute

  6. alice

    3 months ago

    I have COPD. 2-14-14 I crashed. I had double pneumonia 17% lung function and CO2 over 106. I was on a ventilator for 7 days….hospital 20 days and at the time was a smoker and being treated for COPD. I was not on 02 at this point. Until 2-14-14 hehe on 1 1/2 liters since. Been through PULMONARY rehab been evaluAted for double lung transplant but at this time am going to try lung reduction. I am at 22% lung function. Surgery date is Oct 4, 2016. Do you think stem cell could be more beneficial?

  7. Charlotte Davis

    3 months ago

    Why are there no follow up visit or data after one year? Are the stem cells effective for only a short period of time? To be useful as results, longer period of regeneration must be known.
    Thanks, Charlotte, CA.

  8. PB

    3 months ago

    Dear Justine,

    First and foremost, it’s great that you have been able to stay smoke-free and that you are in remission from lung cancer. We would be happy to discuss candidacy, stem cells, cost and any questions you may have. So, feel free to contact us at (855) 313-1149 to speak one-on-one with a patient coordinator. We look forward to hearing from you soon.

    Kind Regards,

    The Lung Institute

  9. Justine

    3 months ago

    I found out that I had COPD after I stopped smoking and than I found out I had lung cancer which was almost five years ago. I am now on oxygen now I’m not on any meds. just two inhales
    My cancer is in remission. So would I be able to have stem cell ? Just would like to kick my self for ever picking up that first Cig. God bless all of you who are in the fight.

  10. PB

    4 months ago

    Dear Mike,

    First and foremost, we’re sorry to hear of the loss of your wife from COPD. Currently. there is only one known genetic cause of COPD, and it’s called alpha-1 antitrypsin deficiency. While having alpha-1 antitrypsin deficiency is rare, there are people who have COPD because of the deficiency. We extend our deepest sympathies to you and your family during this difficult time.

    Kind Regards,

    The Lung Institute

  11. Mike

    4 months ago

    Why no mention of genetics? My wife joined her mother and four siblings in premature death from COPD.She did outlast the others in age, due to a one lung transplant and more advanced care. In the end lung cancer in the old, failed lung coupled with a late diagnosis and delayed treatment by a medical system I am convinced “triaged” her to death.

  12. bridgette

    6 months ago

    we have started a go fund me page to help with the cost and traveling cost. we r almost there and then we can set a date.
    so if anyone is need make a GO FUND ME PAGE
    also check with your local church’s, my daughters church is donating a large amount.
    also some bowling alleys will help you do a fundraiser. i hope this is helpful to all.

  13. PB

    6 months ago

    Dear Sandra,

    We’re sorry to hear that you’ve been going through such a difficult time. Quitting smoking can be very challenging, so we hope that you find our article about tips to quit smoking helpful. To best answer your question regarding your PFT number, it’s important to talk with your doctor. Because your doctor knows you, your PFT results and your health the best, he or she will be able to answer your questions and address any concerns you have. Keep us updated about your progress quitting smoking, and feel free to contact us to learn more about stem cell treatment by calling (855) 313-1149.

    Kind Regards,

    The Lung Institute

  14. Sandra k Rompies

    6 months ago

    My lung doctor did the PFTest and the 6 minute walk on me. It came back she said that 2 years ago it was in the teens, and now it’s 700. What does that mean? I have been on oxygen 24/7 for about 4 years now, but I still smoke and still trying every thing to quit but all I can do is cut down, but still trying. I have COPD, asthma. Just don’t understand the 700 on my test, she did put me on a antibiotic,and now 4 inhalers. I also use a nubulizer with 3 different meds in it. Please try to answer my PFT number. Thank You in Cincinnati…

  15. Cameron Kennerly

    8 months ago

    Good afternoon Liz,

    That’s an excellent question Liz and we thank you for your feedback. Although the primary pathophysiology of pulmonary fibrosis is scarring of the lungs, compared to inflammation in COPD, the inherent anti-inflammatory effects of stem cell therapy are known to have an effect on pulmonary fibrosis as well as COPD. Although we have a limited data-set on pulmonary fibrosis treatments, of the patients we’ve treated with the disease, 66% have seen improvement. If you’d like more information on stem cell treatment please feel free to call us at (855) 313-1149 to speak with one of our patient coordinators.

    Thanks again for your question Liz,

    -The Lung Institute

  16. Cameron Kennerly

    8 months ago

    Hello Susie,

    Although we aren’t currently offering any form of clinical research trial, we sympathize with your condition and applaud you for your discipline in quitting smoking. Your active daily routine is also something to be proud of. We’d like to recommend that you browse through some of our previous articles for lifestyle and nutrition tips to improve your quality of life. Some of our most popular have been Juice Recipes, Helpful Herbs, Apple Cider, Natural Purifiers, and Plants.

    Please keep us updated on your progress Susie and thanks for dropping in!

    -The Lung Institute

  17. Cameron Kennerly

    8 months ago

    Hello Allen,

    To begin, we’d like you to know we share your frustrations in this form of treatment’s lack of insurance coverage. It is this reason that we work so diligently to inform those who suffer from chronic lung disease on natural and alternative treatment options when traditional options fail. Because of this lack of insurance coverage, we keep meticulous records of our previous patients and their progress, in order to publish our research and further push this form of medicine into mainstream acceptance.

    Given the complexity of the human body in response to any medicine, it’s impossible to guarantee a specific outcome. However we are proud of the fact that 84% of our patients found their quality of life to improve within 3 months of treatment and nearly half saw their pulmonary function improve over 10%.

    Due to voices like yourself, this form of treatment is gradually moving into broader acceptance for the betterment of those who suffer from COPD. We appreciate your feedback and thank you for joining the discussion. If you have any further questions, please feel free to reach out to us at (855) 313-1149 to speak with one of our knowledgeable patient coordinators.

    Thanks again Allen,

    -The Lung Institute

  18. Cameron Kennerly

    8 months ago

    Good Afternoon Lynn,

    Thanks for following up for clarification. Our qualifying standard regarding having cancer previously is that you must be in remission for a period longer than five years. If you meet this condition, please feel free to call us back at (855) 313-1149 to speak with one of our patient coordinators.

    Thanks for checking back in Lynn,

    -The Lung Institute

  19. lynn

    8 months ago

    From previous phone call I was told if you’ve had previous cancer, you were not eligible for this treatment. Is this correct?

  20. Cameron Kennerly

    8 months ago

    Hello Pat,

    Although you have our deepest sympathies regarding your COPD diagnosis, we’re glad to hear that your health at this point in time is at such a high level. You live a truly admirable lifestyle. Regarding whether to pursue stem cell therapy at present or postpone it until you notice a decline in your pulmonary health, we would advise pursuing stem cell treatment sooner rather than later as the physiological effects of COPD are ultimately damaging, causing the lung’s bronchioles to lose their shape and the walls of the alveoli to be destroyed. Stem cell therapy works to promote healing within the lungs, so it is advantageous that your lungs are in the best possible shape before beginning this process.

    Please call us today at (855) 313-1149 for more information. Our knowledgeable and friendly patient coordinators are here to answer any questions you may have regarding stem cell therapy and treatment.

    Hope this helps Pat,

    -The Lung Institute

  21. Allen Klinefelter

    8 months ago

    I checked with my pulmonary doctor and she was not recommending the stem cell treatment. She advised me after extensive research of your material and others find no real assistance, except in early stage COPD. The $7,500 dollar fee as well as not being located near me increases the costs even more. I understend that big pharma has a lot of control over the conversation to keep selling their drugs, but it would seem to me if you beleive in this treatment so much, you would drastically increase your research study so that main stream medical community would recommend your treatment and then insurance companies would cover the treatment. Many of your patients are elderly living on fixed income or on disability which is also fixed income. The result in my mind is that this is a way to separate the desperate from their small incomes in hopes this will work. Maybe if you offered a guarantee of 50 or 75% improvement in lung capacity verified by an independent pulmonary specialist or you money back. You stand to make a fortune if you can prove your treatment to the medical and insurance community.

  22. Susie Chartrand

    8 months ago

    Is there a cost free research project I could participate in? I really think this process would help me but I just don’t have the money to do it on my own. I’m a firm believer the earlier I can get help the better off I will be. I was able to quit smoking. I started using a nebulizer and I have 3 inhailers to use to help me breath. I also was able to start treating my sleep apnea. I do small streatc exercises , and try to stay busy doing a variety of daily projects. So as you can see I am trying to be very proactive about my health. It’s been about 2 years since all the changes started. But I’m not noticing any improvement! So a research study may help me. Thank you so much for your time and help.

  23. Cameron Kennerly

    8 months ago

    Hello Gordon,

    Although we respectfully disagree with your opinion, your feedback and time in reading our study is very much appreciated. In response to your concerns over a lack of meaningful research provided in our study, we’ve cited the New England Journal of Medicine, The Lancet, and the European Respiratory Journal–among others– detailing the use of stem cell therapy in the treatment of chronic lung disease throughout our paper. In reference to the Mayo Clinic, in fact, they are actively researching Stem Cell Therapy and Regenerative medicine as an alternative treatment method for illnesses ranging from Cardiovascular Disease to Parkinson’s.

    We hope this information was helpful and if you ever have any questions regarding stem cell therapy or the efficacy of our treatment process, please contact us at (855) 313-1149 and our patient coordinators would be happy to help!


    -The Lung Institute

  24. pat clark

    8 months ago

    At present, I can maintain a 2.7 miles per hour walk at an 8% grade with a 15 lb. backpack for 70 minutes, at sea level, and do so at least twice a week. I have been diagnosed with copd of recent and wonder if it might be early days for such a procedure as you offer, or would the benefit be greater now than at a later more progressed stage?

  25. Liz Skinnon

    8 months ago

    Dear Lung Institute ,
    Are there any pilot studies on Autologoys Stem Cells Therapy and its effects on Pulmonary Fibrosis. My Husband Daniel Skinnon does not believe this therapy applies to him because the fibrosis has grown on the lung cells and he does not believe there is room for new cell growth on top of scar tissue. So he has convinced himeself his case is hopeless Can anyone counter that argument is does area space on lung tissue matter ?
    Please respond
    Mre Skinnon

  26. gordon faulkner

    8 months ago

    Sounds like a fraud to me, no meaningful research to support the treatment. Mayo doesn’t support it.

  27. Cameron Kennerly

    8 months ago

    Hello David,

    First and foremost we’d like to thank you for your feedback and time in reading our research. In response to your question, because the cost of treatment is dependent on the type of treatment itself, the individual, their disease, its stage, and their current health condition, it varies widely. However, we wholeheartedly empathize with you. In time, and with the voices of individuals like yourself, we believe insurance companies will gradually embrace this form of treatment and widen its availability to all. To see if you qualify for treatment and get a quote, please call us today at (855) 313-1149. Our patient coordinators are knowledgeable and friendly, and are here to answer any questions you may have regarding stem cell therapy and treatment.

    Hope this helps David,

    -The Lung Institute

  28. David Fryatt

    8 months ago

    I would like to ask what is the cost for this kind of treatment? My wife cut her finger last year and it cost us nearly 4 thousand dollars for about 5 stitches and the work of Nurse practitioner for 10 minutes. I dread to think how much this treatment costs and I know you will not answer me in this forum, but I am guessing this is in the tens of thousands on average and of course our wonderful insurance companies will not pay a dime due to it being “Experimental”. So please…your views on costs would be most appreciated?

  29. Cameron Kennerly

    8 months ago

    Hello Pansy,

    First we’d like to start by saying thank you for your great questions. In response to your first question, unfortunately it is not possible for us to know the extended lifespan of a patient that has undergone our treatment against receiving a transplant at this time, as we do not collect patient data after one year. Our current follow-up process involves convening with the patient at 3-months, 6-months, and 1 year post-treatment. Addressing your second question on FEV1 and Six Minute Walk data, our post-treatment PFT data incorporates the FEV1, however six minute walk data varies as it is reported electively by the patient themselves. Because of this, it is not currently standardized as a metric within our post-treatment data. In reference to NIH classification of stem cell therapy being experimental or not, it generally varies by the type of treatment and work done with stem cells. Concerning iPS or embryonic stem cells, the work may be considered experimental, but in contrast, work with bone marrow transplants is not considered experimental at all. Lastly, in regards to your question concerning transplant list data, that is not currently a metric we measure from our incoming patients. Although those were concise answers to complex questions, for more detailed information please feel free to contact one of our patient coordinators at (855) 313-1149. We look forward to hearing from you.


    The Lung Institute

  30. Pansy Pia

    8 months ago

    What is the extend lifespan of those given therapy instead of electing transplant? Do you have FEV and six minute walk data supporting efficacy of the treatment in “improving quality of life”?Is the treatment not still experimental as classified by the NIH? Are patients listed on the OPTN data base through UNOS, awaiting transplant while undergoing your therapy? Thanks!

  31. PB

    9 months ago

    Hello Jennifer,

    The white paper was published in mid-January.

    Best Regards,

    The Lung Institute

  32. Jennifer

    9 months ago

    When was this article written?

  33. Cameron Kennerly

    9 months ago

    Hello William,

    Although unfortunately the VA does not currently cover stem cell treatment, if you ever have any questions regarding stem cell therapy or tips for living with lung disease in general, please reach out to us at (855) 313-1149 and we’d be happy to assist.


    -The Lung Institute

  34. William Diekmann

    9 months ago

    Does the VA cover any of the lung institute
    medical procedures? They do use outside facilities depending on the procedure.

  35. PB

    9 months ago

    Hi Danny,

    Unfortunately, Medicare and other insurance plans do not cover this treatment at this time. It will likely be a few more years before we see insurance coverage for this treatment. However, you can learn more about treatment options, cost, and stem cells in general by speaking with one of our well-qualified patient coordinators. Please give us a call at (855) 313-1149.

    We look forward to hearing from you soon.


    The Lung Institute

  36. Danny maness

    9 months ago

    Does any insurance cover the cost for this

  37. Cameron Kennerly

    9 months ago

    Hello Jeff,

    It’s great to hear that in conjunction with your stem cell therapy treatment, the Swanson vitamins you’ve described have had such a large effect on your pulmonary health. We will most certainly look into these vitamins and we appreciate your interest and feedback. Here at the Lung Institute our goal is to provide the most effective treatments for our patients with the goal of improving quality of life overall, so any new science or information to aid in that goal is always welcomed.

    Thanks for the feedback Jeff,

    -The Lung Institute

  38. jeff s

    9 months ago I am now on these pills after stem cell and pretty much without oxygen now,.. please look at this medication to go with your procedure,.. I was almost dead before, lung capacity was 3%..jeff s

Your Comment

Your email address will not be published.

* All treatments performed at Lung Institute utilize autologous stem cells, meaning those derived from a patient's own body. No fetal or embryonic stem cells are utilized in Lung Institute's procedures. Lung Institute aims to improve patients' quality of life and help them breathe easier through the use of autologous stem cell therapy. To learn more about how stem cells work for lung disease, click here.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

Under current FDA guidelines and regulations 1271.10 and 1271.15, the Lung Institute complies with all necessary requirements for operation. Any individual who accesses Lung Institute's website for information is encouraged to speak with his or her primary physician for treatment suggestions and conclusive evidence. All information on this site should be used for educational and informational use only.